Drugs Made In America Acquisition Corp.

Nasdaq:DMAANasdaq:DMAARNasdaq:DMAAU

Blank Checks·FORT LAUDERDALE, FL

CEO

Stockwell Lynn

CFO

Worman Glenn C.

Summary Financials

Revenue

—

Adj. EBITDA

—

Net Income

-$279,845

FY 2024

EPS (Diluted)

-$0.03

FY 2024

Stock Price

$10.47

+0.0%

2026-03-06

52W Range

$9.98 – $10.48

P/E Ratio

-349.0x

Market Cap

$350.9M

Cash

$1,351

FY 2024

Total Debt

—

Net Cash

$1,351

Enterprise Value

$350.9M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

—

Adj. EBITDA

—

Net Income

-$279,845

FY 2024

EPS (Diluted)

-$0.03

FY 2024

Stock Price

$10.47

+0.0%

2026-03-06

52W Range

$9.98 – $10.48

P/E Ratio

-349.0x

Market Cap

$350.9M

Cash

$1,351

FY 2024

Total Debt

—

Net Cash

$1,351

Enterprise Value

$350.9M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—